<DOC>
	<DOC>NCT01770795</DOC>
	<brief_summary>To evaluate the efficacy and safety Genexol-PM(CrEL-free polymeric micelle formulated paclitaxel)and gemcitabine in untreated metastatic NSCLC patients</brief_summary>
	<brief_title>A Phase II Trial of Genexol-PM and Gemcitabine in Patients With Advanced Non-small-cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>age over 18 histologically or cytologically confirmted nonsmall cell lung cancer stage IIIb with pleural effusion or stage IV ECOG PS 02 at least one measurable lesion expected life span more than 3 months normal bone marrow, liver, renal function no prior chemotherapy or radiotherapy except for whole brain radiotherapy for symptomatic brain metastases more than 6 months from the last adjuvant chemotherapy active infection severe comorbitidies pregnant or lactating women other invasive malignancies poorly controlled symptomatic brain metastases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>genexol-PM</keyword>
	<keyword>paclitaxel</keyword>
</DOC>